Purchase this article with an account.
A. D. Meleth, G. Gensler, T. E. Clemons, J. P. SanGiovanni, E. Y. Chew, Age-Related Eye Disease Study 2 (AREDS2) ResearchGroup; Baseline Nutritional Characteristics of the Age-Related Eye Disease Study 2 (AREDS2) Cohort. Invest. Ophthalmol. Vis. Sci. 2009;50(13):279.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To provide information on dietary and supplement intake in patients with age-related macular degeneration..
AREDS2 is an 82-center phase III randomized trial designed to assess the effects of oral supplementation of high doses of macular xanthophylls (lutein and zeaxanthin) and/or the omega-3 long chain polyunsaturated fatty acids (LCPUFAs) docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA) for prevention of progression to advanced AMD in people at moderate-to-high risk of this event. We collected information on nutritional supplement use and dietary intake using a standardized questionnaire and the Harvard Dietary Assessment. Baseline blood nutrient levels were also measured in 285 participants.
4,203 participants were randomized into the AREDS2. Sixty-four percent of these participants were taking an AREDS-type supplement (beta-carotene, vitamins C and E, and zinc) at the time of enrollment. Prior to randomization 17.5% of the participants were taking a lutein and/or zeaxanthin supplement and 14.6% were taking an omega-3 LCPUFA supplement (DHA, EPA and/or fish oil).
Clinical Trial: :
This PDF is available to Subscribers Only